JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

Kodu・Aktsiate loetelu・Krystal Biotech Inc

Krystal Biotech Inc

Avatud

SektorTervishoid

269.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

268.98

Max

275.3

Põhinäitajad
By Trading Economics
Sissetulek	-28M 51M
Müük	9.3M 107M
P/E Sektori keskmine	40.483 60.328
Kasumimarginaal	47.99
Töötajad	295
EBITDA	-10M 40M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+20.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	123M 8.1B
Eelmine avamishind	269.21
Eelmine sulgemishind	269.21

Uudiste sentiment

By Acuity

17%

83%

35 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

133.221 / 169.73 Toetus ja vastupanu

Krystal Biotech Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. apr 2026, 23:08 UTC

Tulu

Suurimad hinnamuutused turgudel

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. apr 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. apr 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. apr 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. apr 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. apr 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. apr 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. apr 2026, 22:10 UTC

Tulu

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. apr 2026, 21:56 UTC

Tulu

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. apr 2026, 21:44 UTC

Tulu

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. apr 2026, 21:43 UTC

Tulu

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. apr 2026, 20:39 UTC

Tulu

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Võrdlus sarnastega

Hinnamuutus

Krystal Biotech Inc Prognoos

Hinnasiht

By TipRanks

20.04% tõus

12 kuu keskmine prognoos

Keskmine 327.13 USD 20.04%

Kõrge 371 USD

Madal 284 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Krystal Biotech Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Krystal Biotech Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

133.221 / 169.73Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

35 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.